Nutex Health Inc.(NUTX)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #169 of 2,879 stocksTOP 10%
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
NUTX Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Nutex Health Inc. (NUTX), a Industrials sector company. 13F Pro's AI-powered ranking engine scores NUTX at 74.0/100 on a 32-signal composite quality model, placing it at rank #169 of 2,879 stocks — the top 10% of the AI-ranked universe. NUTX scores in the top quartile across revenue growth (95.5), balance sheet strength (89.2), free cash flow (83.6). Areas of concern include earnings quality (30.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 14.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Nutex Health Inc. reports quarterly revenue of $216.5M, net income of $46.8M, an operating margin of 37.5%. Top institutional holders of NUTX by reported 13-F value include BlackRock,, Pertento Partners LLP, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. NUTX trades on the Nasdaq exchange and files with the SEC under CIK 1479681. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NUTX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Nutex Health Inc. directly from SEC EDGAR. Nutex Health Inc.'s 13F Pro composite quality score has ranged between 8 and 80 since 2022, currently 74.0 — a stable long-term trajectory across 50 quarterly and live scoring snapshots.
Revenue
Q1 2026
$216.5M
Net Income
Q1 2026
$46.8M
Free Cash Flow
Q1 2026
$74.3M
Operating Margin
Q1 2026
37.5%
D/E Ratio
Q1 2026
0.12
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
+253.4% YoYNet Income
+254.6% YoYOperating Income
+967.5% YoYEPS (Diluted)
+655100.0% YoYTotal Assets
+130.6% YoYTotal Debt
+14.5% YoYOp. Cash Flow
+19639.5% YoY| Metric | FY 2025 | FY 2023 | FY 2022 | FY 2021 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|
| Revenue | $875.3M +253.4% | $247.6M +12.9% | $219.3M -33.9% | $331.5M | $0.00 -100.0% | $474.7K |
| Net Income | $70.8M +254.6% | $-45.8M +89.2% | $-424.8M -420.4% | $132.6M +1884.0% | $-7.4M -8968.1% | $83.8K |
| Operating Income | $275.6M +967.5% | $-31.8M +92.2% | $-406.6M -338.8% | $170.3M +38055.1% | $-448.6K +15.8% | $-533.0K |
| EPS (Diluted) | $10.48 +655100.0% | $-0.00 +89.3% | $-0.01 -406.1% | $0.00 | — | — |
| Total Assets | $918.5M +130.6% | $398.2M -7.8% | $431.8M +9.4% | $394.7M +77155.9% | $510.8K -93.3% | $7.6M |
| Total Debt | $42.5M +14.5% | $37.1M +4.3% | $35.6M -80.0% | $178.3M | — | — |
| Operating Cash Flow | $248.1M +19639.5% | $1.3M -97.5% | $50.6M -70.8% | $173.4M +63345.1% | $-274.2K -710.6% | $44.9K |
Get alerted when NUTX's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Nutex Health Inc. including:
Top Institutional Holders of NUTX
BlackRock, Inc.
$36.1M379,355 shPertento Partners LLP
$35.5M373,970 shVANGUARD CAPITAL MANAGEMENT LLC
$20.8M219,131 shAMERICAN CENTURY COMPANIES INC
$19.3M203,450 shTopline Capital Management, LLC
$16.9M177,800 shSTATE STREET CORP
$11.7M123,177 shGEODE CAPITAL MANAGEMENT, LLC
$11.6M122,113 shMILLENNIUM MANAGEMENT LLC
$8.5M89,571 shUBS Group AG
$6.6M69,570 shWINMILL & CO. INC
$6.2M65,350 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $36.1M | 379,355 |
| Pertento Partners LLP | $35.5M | 373,970 |
| VANGUARD CAPITAL MANAGEMENT LLC | $20.8M | 219,131 |
| AMERICAN CENTURY COMPANIES INC | $19.3M | 203,450 |
| Topline Capital Management, LLC | $16.9M | 177,800 |
| STATE STREET CORP | $11.7M | 123,177 |
| GEODE CAPITAL MANAGEMENT, LLC | $11.6M | 122,113 |
| MILLENNIUM MANAGEMENT LLC | $8.5M | 89,571 |
| UBS Group AG | $6.6M | 69,570 |
| WINMILL & CO. INC | $6.2M | 65,350 |
More Industrials Companies
View all Industrials →Put NUTX on your watchlist
Track score changes the day Nutex Health Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is NUTX a good stock to buy?
13F Pro's AI-powered analysis of Nutex Health Inc. (NUTX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Industrials sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for NUTX are available on the NUTX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own NUTX?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling NUTX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Nutex Health Inc.'s investment landscape.